Scientific knowledge and our understanding of the human body and diseases have limited any possible treatment tailoring to each patient. The technological advances enabling the integration of various data sets (e.g. ‘-omics', microbiome, epigenetics and environmental exposure) have facilitated a greater understanding of the human body, the molecular basis of disease and all the factors influencing disease onset, progression and response to treatment, thereby ushering in the era of personalized medicine. We evaluate the regulatory approaches available to facilitate early patient access to efficacious and safe compounds in the EU and the USA in order to make more informed recommendations in the future as to the gaps in regulations for early patient access. An in-depth analysis of conditional approvals (EU) and accelerated approvals (USA) is performed based on the publicly available information (European public assessment reports and a summary review of products approved under both programmes). The types of product, indications, time to approval and type of evidence submitted were analysed. Between 2007 and early 2015, 17 products were conditionally approved in the EU and 25 in the USA, most of them in the area of oncology and based on evidence from phase II clinical trial data. Early approval of promising products based on data from early phases of development is already possible in the EU and the USA. Some of the improvements could entail implementing a rolling assessment of evidence in Europe and extending the scope of early dialogues.

Journal Section:
Editor's choice
Keywords:
Early patient access, Conditional approval, Accelerated approval, Personalized medicine, Drug development, Regulation, European Medicines Agency, Food and Drug Administration, Health technology assessment
1.
European Commission: Use of ‘-omics' technologies in the development of personalised medicine. Brussels, European Commission, 2013.
2.
PerMed: Shaping Europe's Vision for Personalised Medicine. Strategic Research and Innovation Agenda (SRIA). Cologne, German Aerospace Center (DLR), 2015. http://www.permed2020.eu/_media/PerMed_SRIA.pdf.
3.
Munoz J, Kurzrock R: Targeted therapy in rare cancers - adopting the orphans. Nat Rev Clin Oncol 2012;9:631-642.
[PubMed]
https://doi.org/10.1038/nrclinonc.2012.160
4.
Leyens L, et al: Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective. Pers Med 2014;11:641-649.
https://doi.org/10.2217/PME.14.55
5.
Berndt ER, Trusheim MR: The segmentation of therapeutic populations in oncology. Health Manage Policy Innovation 2012;1:19-34.
6.
European Medicines Agency. http://www.ema.europa.eu/ema/ (accessed June 15, 2015).
7.
Horgan D, Jansen M, Leyens L, et al: An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. Public Health Genomics 2014;17:287-298.
[PubMed]
https://doi.org/10.1159/000368034
8.
Ferrario A, Kanavos P: Managed entry agreements for pharmaceuticals: the European experience. Brussels, EmiNET, 2013.
9.
US Food and Drug Administration: Fast track, breakthrough therapy, accelerated approval, priority review. http://www.fda.gov/ForPatients/Approvals/Fast/default.htm (accessed June 15, 2015).
10.
US Food and Drug Administration: New drugs at FDA: CDER's new molecular entities and new therapeutic biological products. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm.
11.
European Medicines Agency, Committee for Medicinal Products for Human Use: EMEA/509951/2006: guideline on the conditional marketing authorisation for medicinal products for human use. London, European Medicines Agency, 2006.
12.
European Medicines Agency: European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01 ac058001d124 (accessed June 15, 2015).
13.
US Food and Drug Administration, Center for Drug Evaluation and Research: Novel New Drugs 2011. Washington, US Food and Drug Administration, Center for Drug Evaluation and Research, 2012.
14.
US Food and Drug Administration, Center for Drug Evaluation and Research: Novel New Drugs 2012, Summary. Washington, US Food and Drug Administration, Center for Drug Evaluation and Research, 2013.
15.
US Food and Drug Administration, Center for Drug Evaluation and Research: Novel New Drugs 2013, Summary. Washington, US Food and Drug Administration, Center for Drug Evaluation and Research, 2014.
16.
US Food and Drug Administration, Center for Drug Evaluation and Research: Novel New Drugs 2014, Summary. Washington, US Food and Drug Administration, Center for Drug Evaluation and Research, 2015.
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.